In preclinical models of HER2-positive breast cancer, HER2 reactivation in lapatinib-resistant derivatives was driven by the acquisition of a HER2 L755S mutation, which could be overcome by neratinib or afatinib[28]. This evidence concerns the gene ERBB2 and breast carcinoma.